Georgina V Long Selected Research

Melanoma (Melanoma, Malignant)

12/2022	Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. Reply.
11/2022	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
10/2022	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
10/2022	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
10/2022	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
8/2022	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre.
8/2022	Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
6/2022	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
5/2022	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma.
4/2022	Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Georgina V Long Research Topics

Disease

293	Melanoma (Melanoma, Malignant) 12/2022 - 04/2011
119	Neoplasms (Cancer) 10/2022 - 03/2012
52	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2012
25	Brain Neoplasms (Brain Tumor) 10/2022 - 03/2012
22	Disease Progression 11/2021 - 11/2012
11	Fever (Fevers) 01/2021 - 11/2012
6	Lymphatic Metastasis 01/2022 - 01/2019
6	Autoimmune Diseases (Autoimmune Disease) 11/2021 - 02/2016
5	Body Weight (Weight, Body) 10/2019 - 01/2015
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2015 - 04/2014
4	Inflammation (Inflammations) 01/2022 - 01/2017
4	Pneumonia (Pneumonitis) 01/2022 - 01/2017
4	Uveal melanoma 04/2021 - 01/2020
4	Colitis 01/2021 - 01/2019
4	Fatigue 01/2019 - 01/2015
3	Neutropenia 01/2021 - 11/2012
3	Nevus (Nevi) 01/2019 - 07/2012
2	COVID-19 01/2022 - 01/2021
2	Thyrotoxicosis 01/2022 - 01/2021
2	Hypothyroidism 01/2022 - 01/2021
2	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2019
2	Hepatitis 11/2021 - 01/2021
2	Infections 01/2021 - 11/2018
2	Hypophysitis 06/2018 - 08/2014
2	Pain (Aches) 10/2015 - 05/2015
2	Nausea 05/2015 - 01/2015
2	Carcinogenesis 12/2012 - 07/2012
1	Facial Nerve Diseases (Facial Nerve Disorders) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

59	Immune Checkpoint InhibitorsIBA 05/2022 - 02/2015
58	dabrafenibIBA 01/2022 - 01/2012
54	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2022 - 11/2012
48	IpilimumabIBA 10/2022 - 01/2013
48	trametinibIBA 01/2022 - 11/2012
40	pembrolizumabIBA 01/2022 - 06/2015
36	NivolumabIBA 12/2022 - 01/2015
33	Biomarkers (Surrogate Marker)IBA 06/2022 - 05/2012
20	VemurafenibIBA 01/2018 - 03/2012
18	Pharmaceutical PreparationsIBA 01/2020 - 05/2012
17	DNA (Deoxyribonucleic Acid)IBA 08/2022 - 01/2013
14	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2012
12	AntibodiesIBA 01/2022 - 09/2013
11	LigandsIBA 10/2022 - 07/2015
11	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 03/2016
9	B7-H1 AntigenIBA 01/2022 - 03/2014
9	Circulating Tumor DNAIBA 01/2022 - 12/2015
9	Dacarbazine (DIC)FDA LinkGeneric 11/2020 - 01/2012
9	Phosphotransferases (Kinase)IBA 01/2020 - 12/2014
8	Mitogen-Activated Protein KinasesIBA 10/2022 - 01/2012
8	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2020
7	Formaldehyde (Formol)FDA Link 01/2022 - 01/2013
7	SteroidsIBA 11/2021 - 10/2014
6	Biological ProductsIBA 10/2022 - 12/2015
6	ParaffinIBA 01/2022 - 01/2013
6	CytokinesIBA 01/2022 - 03/2014
5	Monoclonal AntibodiesIBA 01/2022 - 01/2017
5	CateninsIBA 12/2017 - 01/2014
5	Proto-Oncogene Proteins B-rafIBA 09/2015 - 09/2013
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2022 - 10/2014
4	Programmed Cell Death 1 ReceptorIBA 01/2022 - 11/2018
4	Cell-Free Nucleic AcidsIBA 11/2020 - 09/2013
3	relatlimabIBA 12/2022 - 01/2022
3	spartalizumabIBA 01/2022 - 10/2020
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2019
3	MART-1 AntigenIBA 12/2021 - 09/2013
3	GlucocorticoidsIBA 11/2021 - 11/2020
3	CTLA-4 AntigenIBA 10/2020 - 03/2014
3	EnzymesIBA 01/2019 - 01/2017
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017 - 03/2014
2	Dihydrotachysterol (AT 10)IBA 11/2022 - 01/2021
2	AntigensIBA 10/2022 - 11/2020
2	bempegaldesleukinIBA 03/2022 - 10/2020
2	Interleukin-2 (IL2)IBA 01/2022 - 06/2014
2	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2021 - 06/2018
2	atezolizumabIBA 01/2021 - 01/2018
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2021 - 11/2020
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2020 - 10/2014
2	ChemokinesIBA 01/2020 - 03/2014
2	PlacebosIBA 01/2020 - 01/2019
2	Messenger RNA (mRNA)IBA 01/2019 - 01/2018
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 04/2014
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2018 - 07/2015
2	tributyl phosphate (TBP)IBA 11/2017 - 10/2014
2	Adenosine (Adenocard)FDA LinkGeneric 01/2017 - 01/2017
2	Glucose (Dextrose)FDA LinkGeneric 07/2015 - 04/2014
1	2- (5- (3- chlorophenyl)- 6- (4- chlorophenyl)- 1- (1- (isopropylsulfonyl)- 3- methylbutan- 2- yl)- 3- methyl- 2- oxopiperidin- 3- yl)acetic acidIBA 10/2022
1	Bispecific AntibodiesIBA 10/2022
1	cyclopropapyrroloindoleIBA 01/2022
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022

Therapy/Procedure

174	Therapeutics 10/2022 - 04/2011
78	Immunotherapy 10/2022 - 09/2012
17	Drug Therapy (Chemotherapy) 04/2022 - 01/2012
9	Radiotherapy 01/2022 - 01/2013
7	Lymph Node Excision (Lymph Node Dissection) 10/2022 - 01/2019
7	Neoadjuvant Therapy 08/2022 - 01/2019
3	Aftercare (After-Treatment) 05/2022 - 03/2012
2	Retreatment 01/2021 - 01/2018
2	Precision Medicine 02/2016 - 12/2012
1	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2022